• CDK1–APE1 Signaling in NSCLC: Synthetic Lethality

  2026-09-30

  A recent Cell Death and Disease study identifies CDK1-mediated phosphorylation of APE1 at Ser54 as a regulatory switch linking DNA repair, cell-cycle control, metastasis, and immune response in NSCLC. The findings support a therapeutic model in which WEE1 inhibition activates CDK1, promotes APE1 degradation, and may enhance both APE1-targeted treatment and anti–PD-L1 therapy, although clinical transferability remains to be established.

• ALC-0315 for mRNA LNP Workflows

  2026-09-30

  ALC-0315 supports controlled lipid nanoparticle development for intracellular mRNA transport and cytoplasmic release, with organic-phase handling and formulation-specific quality control. This workflow also shows how to translate LNP screening principles into more demanding applications such as targeted hematopoietic stem and progenitor cell delivery without confusing a research starting material with a validated clinical formulation.

• Drying mRNA-LNPs: Evidence, Methods, and Limits

  2026-09-29

  Zhen and colleagues provide a literature-based framework for understanding how freeze-drying and alternative drying technologies affect mRNA and other nucleic acid lipid nanoparticles. The review’s central implication is that cargo structure, formulation, drying route, and post-reconstitution potency must be evaluated together rather than treated as interchangeable process variables.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-09-29

  A scenario-based guide to using HotStart™ 2X Green qPCR Master Mix (SKU K1070) for reproducible gene expression and nucleic acid quantification alongside cell viability, proliferation, and cytotoxicity assays. It connects SYBR Green assay design, hot-start specificity, protocol control, and evidence-based interpretation.

• Dabigatran: A Mechanism-to-Readout Research Guide

  2026-09-28

  Dabigatran is more than a direct thrombin inhibitor: it is a decision tool for connecting molecular potency with clinically relevant coagulation readouts. This guide develops a mechanism-to-assay framework for interpreting thrombin inhibition, metabolite effects, pharmacokinetics, and translational limitations.

• Baicalein Workflows for Cancer and Inflammation

  2026-09-28

  Use Baicalein to probe 12-LOX-linked arachidonic acid signaling alongside cancer-cell and inflammatory readouts, with controls that separate pathway effects from general toxicity. A recent neuronal-protection study offers a useful paired-assay design principle—but does not establish Baicalein as a neuroprotectant.

• MnTBAP Chloride: A Redox Assay Design Framework

  2026-09-27

  MnTBAP Chloride offers a practical way to perturb superoxide-linked redox biology, but interpreting a rescue requires more than measuring reactive oxygen species alone. This article turns chronic-stress rat findings into an assay-design framework for separating mitochondrial function, inflammation, and behavioral outcomes.

• Dabigatran Etexilate: Oral Thrombin Inhibition

  2026-09-26

  Blommel and Blommel’s 2011 clinical review describes dabigatran etexilate as an orally administered prodrug that delivers reversible, direct thrombin inhibition without the routine INR monitoring associated with vitamin K antagonists. The review highlights evidence across venous thromboembolism prevention, nonvalvular atrial fibrillation, and acute VTE treatment, while emphasizing bleeding risk, gastrointestinal effects, and renal-function-based dosing considerations.

• Gly-Gly-Phe-Gly: A Conjugation Research Workflow

  2026-09-25

  Gly-Gly-Phe-Gly (GGFG) is a flexible peptide spacer for designing and evaluating peptide-based conjugates—but it is not a universal coupling reagent. This workflow pairs careful linker characterization with the combination-testing logic of a multiple-myeloma study, while clearly separating that study’s drug findings from GGFG applications.

• Optimized GBA1 mRNA for Gaucher Disease

  2026-09-25

  The study optimized human GBA1 mRNA by modifying untranslated regions, codon usage, and poly(A) tails, producing higher and more sustained glucocerebrosidase activity in cell models. Its cell-rescue and mouse data support further investigation of mRNA–LNP delivery, while leaving key questions about disease-model efficacy, tissue distribution, and clinical translation open.

• Digoxin: Na+/K+ ATPase Pump Inhibitor Research

  2026-09-24

  Digoxin is a Na+/K+ ATPase pump inhibitor used in cardiac contractility and arrhythmia research. Product information describes its handling properties and reports cell-dependent chikungunya virus inhibition, while the available findings do not establish clinical antiviral efficacy.

• Cell Cycle Assay Kit: From DNA Content to Decisions

  2026-09-24

  DNA-content profiling can reveal how a treatment reshapes proliferation and cell death—but only when read in the context of mechanism and experimental design. This article connects PI-based flow cytometry to translational strategy, with practical guidance for using the Cell Cycle Assay Kit (Catalog No. K2263).

• CB-839 (Telaglenastat) in Cancer Metabolism

  2026-09-23

  Use CB-839 to test whether GLS1-dependent glutaminolysis supports cancer-cell survival, then pair metabolic readouts with growth, apoptosis, or autophagy assays. A PRMT5 study in MYCN-amplified neuroblastoma offers a rationale for probing glutamine metabolism—but does not establish that CB-839 works in that model.

• PRMT5 Splicing Vulnerability in MYCN Neuroblastoma

  2026-09-23

  The reference study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-controlled RNA splicing, with downstream disruption of epitranscriptomic regulation and glutamine metabolism. Its integrated transcriptomic, isotope-tracing, and mouse-model evidence provides a mechanistic framework for cancer metabolism research and for designing experiments that distinguish spliceosomal regulation from direct glutaminolysis inhibition.

• Fractional Viability in In Vitro Cancer Drug Studies

  2026-09-22

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth inhibition and cell killing should not be treated as interchangeable drug-response outcomes. This framework helps researchers interpret anticancer screens more precisely and design assays that separate proliferative arrest from cytotoxicity.

8128 records 1/542 page Next 12345 下5页 Last page